A statistically significant difference in efficacy favoring RPV/FTC/TDF was demonstrated for participants with baseline HIV-1 RNA 100000 copies/ml or less [ ( n = 510 ) 88.8 % RPV/FTC/TDF vs. 81.6 % EFV/FTC/TDF ( difference 7.2 % , 95 % CI 1.1-13 .4 % ) ] .